NASDAQ$NVCR
Novocure Ltd · Q2 2026 earnings
Q2 2026 earnings · · Before market open · Investor relations
Briefing
Novocure Ltd reported net revenues of $183.6 million and a net loss of $15.7 million for Q2 2026.
The company achieved 16% year-over-year revenue growth driven by 18% growth in active patients globally. Gross margin improved to 78% due to manufacturing efficiencies and a tariff refund. Operating expenses remained elevated due to new indication launches in pancreatic cancer and NSCLC.
- Q2 2026 net revenues reached $183.6 million, up 16% from $158.8 million in Q2 2025.
- Active patients grew 18% to 5,128, with strong contributions from the US, Germany, France and Japan.
- Gross margin expanded to 78% supported by lower array costs and a $4.9 million tariff refund.
- Net loss narrowed to $15.7 million from $40.1 million as revenue growth outpaced operating expense increases.
Headline financials
Revenue & EPS history
Novocure · Revenue · Quarterly
$184M
Forward guidance
Management continues to focus on new indication launches and supply chain optimization amid evolving tariff environment.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-0.5%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+2.6%
Avg return
30 days after
49%
21 / 43 earnings
Positive
+27.5%
Q1 2026
Best reaction
-34.3%
Q2 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | +27.5% | +33.1% | +42.8% | |
| Q4 2025 | -7.9% | -11.3% | -26.8% | |
| Q3 2025 | -4.7% | -11.0% | -5.0% | |
| Q2 2025 | -0.3% | +3.9% | +4.6% | |
| Q1 2025 | +4.4% | +2.9% | +4.3% | |
| Q4 2024 | -12.4% | -17.2% | -14.1% | |
| Q3 2024 | -10.1% | -1.8% | +18.7% | |
| Q2 2024 | +1.2% | +24.2% | -4.1% | |
| Q1 2024 | +16.0% | +21.9% | +72.8% | |
| Q4 2023 | -2.6% | +4.4% | -15.4% | |
| Q3 2023 | -10.2% | -5.5% | -11.4% | |
| Q2 2023 | -17.4% | -19.1% | -26.2% | |
| Q1 2023 | +3.5% | +6.2% | +20.6% | |
| Q4 2022 | -6.1% | -6.1% | -30.3% | |
| Q3 2022 | +3.5% | +8.1% | +10.8% | |
| Q2 2022 | -8.1% | -5.1% | +11.9% | |
| Q1 2022 | -0.5% | +8.9% | +9.1% | |
| Q4 2021 | +10.1% | +10.5% | +9.8% | |
| Q3 2021 | -7.4% | -2.8% | -12.4% | |
| Q2 2021 | -15.3% | -18.0% | -25.9% | |
| Q1 2021 | -0.7% | -4.0% | -0.7% | |
| Q4 2020 | -13.9% | -11.6% | -28.1% | |
| Q3 2020 | +5.8% | -1.4% | +9.9% | |
| Q2 2020 | +11.5% | +14.9% | +20.6% | |
| Q1 2020 | -17.8% | -12.8% | -8.3% | |
| Q4 2019 | -8.4% | -12.7% | -17.6% | |
| Q3 2019 | +1.5% | +4.3% | +24.1% | |
| Q2 2019 | +11.2% | +17.3% | +30.3% | |
| Q1 2019 | +13.0% | +10.0% | +22.7% | |
| Q4 2018 | +4.0% | -2.5% | -10.8% | |
| Q3 2018 | -23.6% | -22.9% | -29.6% | |
| Q2 2018 | -6.7% | -9.2% | +6.8% | |
| Q1 2018 | +11.2% | +14.3% | +25.7% | |
| Q4 2017 | -10.4% | -1.9% | +1.9% | |
| Q3 2017 | +7.5% | +19.3% | +4.7% | |
| Q2 2017 | +4.3% | +2.3% | +2.1% | |
| Q1 2017 | +3.2% | +8.2% | +16.4% | |
| Q4 2016 | -3.5% | +6.3% | -1.4% | |
| Q3 2016 | +13.4% | +21.8% | +34.5% | |
| Q2 2016 | -34.3% | -31.6% | -31.6% | |
| Q1 2016 | +2.3% | — | — | |
| Q4 2015 | +24.7% | — | — | |
| Q3 2015 | +22.3% | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro